News

Global studies from LEO Pharma highlight the diagnostic gaps, quality-of-life burdens, and treatment landscape for patients with CHE.

Subgroups more likely to respond included women and those with shorter-duration, less-extensive hair loss.

New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.

SkinGPT by Haut.AI uses AI to visually simulate skin care results, empowering inclusive, personalized skin care and bridging clinical data with patient insight.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about abrocitinib's flexible dosing for atopic dermatitis, plant-derived exosomes in regenerative skin care, psychosocial support in hidradenitis suppurativa care, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

Adam Friedman, MD, FAAD, discusses the growing need for psychosocial support in hidradenitis suppurativa care and HS Connect’s role in closing the gap.

Discover essential sun protection strategies from Dr. Susan Taylor, focusing on the impacts of UV, visible light, and personalized sunscreen choices.

A new comparative study evaluated positive outcomes from patient use of a gua sha versus a facial roller over 8 weeks of treatment.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

In celebration of Men's Health Month, Hershel Dobkin, MD, FAAD, shed some light on a "taboo" topic.

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil reduced shedding and improved hair density.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the first day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Recent research outlined 5 subtypes of vitiligo that can be used to guide therapeutic choices.

Alys plans to conduct a phase 1/1b trial assessing the efficacy and safety of the mast cell selective c-Kit inhibitor in the CIndU subtype.

Aaron Farberg, MD, led a panel exploring the challenges of diagnosing and treating generalized pustular psoriasis and the promise of targeted therapies.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

Data presented at EULAR 2025 showcased Tremfya's efficacy as the only IL-23 inhibitor to demonstrate inhibition of this nature in psoriatic arthritis.

Discover the future of regenerative skincare with Skin Moderne’s groundbreaking Exosomes Regenerative Complex, a plant-derived innovation led by Dr. Frank Roesken, MD, PhD.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

At the Fall Clinical PA/NP 2025 Conference, attendees caught up on the ins and outs of CHE.

This review of the latest dermatologic studies includes insights into skin improvement with injectable hyaluronic acid, burden of chronic spontaneous urticaria, and more.